Загрузка...
Development of systemic therapy for hepatocellular carcinoma at 2013: Updates and insights
A growing number of multi-targeted tyrosine kinase inhibitor (TKI) has undergone testing for hepatocellular carcinoma (HCC). Unfortunately, this enthusiasm has recently been discouraged by a number of negative phase III studies on several anti-angiogenic TKIs in HCC. Several postulations have been m...
Сохранить в:
| Главные авторы: | , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Baishideng Publishing Group Co., Limited
2014
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3964385/ https://ncbi.nlm.nih.gov/pubmed/24696599 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v20.i12.3135 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|